Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
Immunology Unit, Department of Microbiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Sci Rep. 2024 Aug 22;14(1):19544. doi: 10.1038/s41598-024-70526-z.
Primary liver cancer is the third leading cause of cancer-related mortality. The increasing prevalence of metabolic syndrome and alcohol consumption, along with the existing burden of viral hepatitis, could significantly heighten the impact of primary liver cancer. However, the specific effects of these factors in the Asia-Pacific region, which comprises more than half of the global population, remain largely unexplored. This study aims to analyze the epidemiology of primary liver cancer in the Asia-Pacific region. We evaluated regional and national data from the Global Burden of Disease study spanning 2010 to 2019 to assess the age-standardized incidence, mortality, and disability-adjusted life years associated with primary liver cancer in the Asia-Pacific region. During the study period, there were an estimated 364,700 new cases of primary liver cancer and 324,100 deaths, accounting for 68 and 67% of the global totals, respectively. Upward trends were observed in the age-standardized incidence rates of primary liver cancer due to metabolic dysfunction-associated fatty liver disease (MASLD) and alcohol-associated liver disease (ALD) in the Asia-Pacific region, as well as an increase in primary liver cancer from Hepatitis B virus infection in the Western Pacific region. Notably, approximately 17% of new cases occurred in individuals aged 15-49 years. Despite an overall decline in the burden of primary liver cancer in the Asia-Pacific region over the past decade, increases in incidence were noted for several etiologies, including MASLD and ALD. However, viral hepatitis remains the leading cause, responsible for over 60% of the total burden. These findings underscore the urgent need for comprehensive strategies to address the rising burden of primary liver cancer in the Asia-Pacific region.
原发性肝癌是癌症相关死亡的第三大主要原因。代谢综合征和饮酒的流行率不断上升，加上现有的病毒性肝炎负担，可能会显著增加原发性肝癌的影响。然而，这些因素在亚太地区（占全球人口的一半以上）的具体影响在很大程度上仍未得到探索。本研究旨在分析亚太地区原发性肝癌的流行病学。我们评估了 2010 年至 2019 年全球疾病负担研究的区域和国家数据，以评估亚太地区原发性肝癌的年龄标准化发病率、死亡率和伤残调整生命年。在研究期间，估计有 364700 例原发性肝癌新发病例和 324100 例死亡病例，分别占全球总数的 68%和 67%。由于代谢功能障碍相关脂肪性肝病（MASLD）和酒精相关肝病（ALD）在亚太地区，以及乙型肝炎病毒感染在西太平洋地区导致原发性肝癌的年龄标准化发病率呈上升趋势。值得注意的是，约 17%的新发病例发生在 15-49 岁的人群中。尽管在过去十年中，亚太地区原发性肝癌的负担总体呈下降趋势，但几种病因的发病率有所上升，包括 MASLD 和 ALD。然而，病毒性肝炎仍然是主要原因，占总负担的 60%以上。这些发现强调了在亚太地区需要采取全面的策略来应对原发性肝癌负担的上升。
